Despite six decades of clinical experience with the
polymyxin class of
antibiotics, their dose-limiting nephrotoxicity remains difficult to predict due to a paucity of sensitive
biomarkers. Here, we evaluate the performance of standard of care and next-generation
biomarkers of renal injury in the detection and monitoring of
polymyxin-induced
acute kidney injury in male Han Wistar rats using
colistin (
polymyxin E) and a
polymyxin B (PMB) derivative with reduced nephrotoxicity, PMB nonapeptide (
PMBN). This study provides the first histopathological and
biomarker analysis of
PMBN, an important test of the hypothesis that
fatty acid modifications and charge reductions in
polymyxins can reduce their nephrotoxicity. The results indicate that alterations in a panel of urinary kidney injury
biomarkers can be used to monitor histopathological injury, with Kim-1 and α-GST emerging as the most sensitive
biomarkers outperforming clinical standards of care, serum or plasma
creatinine and blood
urea nitrogen. To enable the prediction of
polymyxin-induced nephrotoxicity, an in vitro cytotoxicity assay was employed using human proximal tubule epithelial cells (HK-2). Cytotoxicity data in these HK-2 cells correlated with the renal toxicity detected via safety
biomarker data and histopathological evaluation, suggesting that in vitro and in vivo methods can be incorporated within a screening cascade to prioritize
polymyxin class analogs with more favorable renal toxicity profiles.